Correction

This article refers to:

VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

Article title: VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

Authors: Sarah Low, Haixia Wu, Kavita Jerath, Annette Tibolla, Birgit Fogal, Rebecca Conrad, Margit MacDougall, Steven Kerr, Valentina Berger, Rajvee Dave, Jorge Villalona, Lynn Pantages, Jennifer Ahlberg, Hua Li, Diane Van Hoorick, Cedric Ververken, John Broadwater, Alisa Waterman, Sanjaya Singh, Rachel Kroe-Barrett

Journal: mAbs

Bibliometrics: Volume 12, Number 1, pages 1-12

DOI: https://doi.org/10.1080/19420862.2019.1709322

It has been noted by the authors that the author name ‘Deborah Webb’ was not included at the time of publication, it was omitted from the article in error. The author list has been corrected as shown below. The authors apologize for any inconvenience caused.

Sarah Low^a, Haixia Wu^a, Kavita Jerath^a, Annette Tibolla^b, Birgit Fogal^b, Rebecca Conrad^b, Deborah Webb^c, Margit MacDougall^b, Steven Kerr^b, Valentina Berger^b, Rajvee Dave^b, Jorge Villalona^b, Lynn Pantages^b, Jennifer Ahlberg^d, Hua Li^d, Diane Van Hoorick^e, Cedric Ververken^e, John Broadwater^b, Alisa Waterman^b, Sanjaya Singh^a, and Rachel Kroe-Barrett^a

^aBiotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; ^bCardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; ^cImmunology and Respiratory Diseases, Boehringer Ingelheim Pharmaceuticals Inc; ^dBiotherapeutics Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; ^eProject Management, Ablynx a Sanofi Company, Zwijnaarde, Belgium